



Australian Government

Department of Health

Office of the Gene Technology Regulator

# OGTR Perspective on Gene Editing


Presentation at the *CSIRO Gene Editing  
of Crops Workshop*  
28-30 November 2017

Dr Andrea Robold  
Regulatory Practice Section  
Office of the Gene Technology Regulator



# Integrated regulation of GMOs & GM Products


- GTR regulates GMOs
- avoid duplicating regulation
- align decision making as far as possible.





# What challenges do new technologies pose for the Gene Technology Regulator?

- New methodologies and applications
  - How do these fit with legislative definitions?
- New techniques that utilise natural processes
  - Are there risks that warrant regulation?
  - How different are the resulting organisms to natural mutants?
  - Should these organisms be regulated as GMOs?





Australian Government  
Department of Health  
Office of the Gene Technology Regulator

# What is a GMO?

Section 10 of the *Gene Technology Act 2000*:


**Gene technology** is any technique for the modification of genes or genetic material

the Regulations can declare techniques not to be gene technology

A **GMO** is

- a) an organism that has been modified by gene technology or
- b) inherited traits that occurred because of gene technology

the Regulations can also declare things to be GMOs or not GMOs





# GT Regulation in the year 2000

not gene  
technology

natural  
mutations

mutagenesis

inserting  
transgenes






# Science – technical advances

2000

2015






# Technical review of the Regulations

## What is the problem?

- Technology has changed since the definitions of 'GMO' and 'gene technology' were last amended
- It's unclear whether organisms modified by some new technologies are GMOs
- New technologies are being used increasingly in research and development, and are moving towards commercialisation





Australian Government  
Department of Health  
Office of the Gene Technology Regulator

# Review of the Regulations

## **Primary aim:**


Bringing the lists of exclusions in the Regulations up to date with current science to provide clarity

## **Main consideration:**

Regulation should be commensurate with the risks posed by gene technology

## **An important constraint:** can't alter the policy settings

- E.g. process trigger







# Review progress to date

First round of consultation was in 2016

- 4 options for how new technologies could be regulated
- options paper and submissions are on the OGTR website

## Public consultation


- on draft amendments to the Regulations
- open until February 2018








# Site-directed nucleases

CRISPR/Cas9, TALENs, ZFN, etc,  
makes a targeted double-strand  
break

non-homologous  
end joining  
  
random indels  
**SDN-1**

  
homology-directed  
recombination guided by an  
added template


  
short template with one  
or several nt difference  
**SDN-2**

  
long template with a  
new sequence  
**SDN-3**



Australian Government  
Department of Health  
Office of the Gene Technology Regulator

# Oligo-directed mutagenesis




Cibus' Rapid Trait  
Development System



# Some new technologies fit 'in-between'

not gene  
technology





# New technologies proposal

Amendment proposal for public consultation – subject to change

natural  
mutations

mutagenesis

SDN-1

## Regulate template-guided changes

Any organism with its genome modified by SDN-2, ODM and SDN-3 will be regulated, whether or not it also contains other genetic modifications, such as a DNA insert for delivery of the technology.

Exclude SDN-1 from regulation

SDN-2 and  
ODM


SDN-3

inserting  
transgenes



# New technologies proposal

Amendment proposal for public consultation – subject to change





# New technologies proposal

Amendment proposal for public consultation – subject to change

natural  
mutations

mutagenesis

SDN-1

SDN-2 and  
ODM

SDN-3

inserting  
transgenes

Key issues for SDN-2 & ODM:

- Submitter concerns depending on parent organism, or repeated use of technique





# New technologies proposal

Amendment proposal for public consultation – subject to change

natural  
mutations

Consistent with current policy settings

mutagenesis

Provides clarity until policy is reviewed

SDN-1

SDN-2 and  
ODM

SDN-3

inserting  
transgenes






Australian Government  
Department of Health  
Office of the Gene Technology Regulator

# Gene drives

- Gene drives are preferentially inherited genetic elements
- 'drive' a trait into a population – including deleterious traits
- Many possible uses have been speculated, including:
  - Disease control, eg virus transmission by mosquitoes
  - Invasive species control, eg rodents, cane toads
  - Agricultural applications, eg fruit fly control, herbicide-resistant weeds, pesticide-resistant insects
- Research is in an early phase: recent proof of concept laboratory experiments in yeast, *Drosophila* and mosquitoes






# Regulatory status of gene drives

- Engineered gene drives involve stable integration of modified genes – these organisms are GMOs
- **Currently:** general plant and animal NLRD categories would include most contained gene drive work
- **Amendment proposal** for public consultation – subject to change: case-by-case assessment of all contained gene drive work (DNIR licence)
  - to be reassessed at the next Regulations Review



# RNA interference




Gene-specific small interfering RNAs may lead to:

- mRNA degradation
- inhibition of mRNA translation
- DNA methylation (represses transcription)



# RNA interference




**Permanent effects:**  
integrated transgene

**Short-term effects:**  
Viral vector

Applied as RNA



# RNA interference




**Permanent effect:**  
integrated transgene

**Short-term effect:**  
Viral vector

Applied as RNA



# RNA interference



**Permanent effect:**  
integrated transgene

**Short-term effect:**  
Viral vector

Applied as RNA



# RNA interference proposal

Amendment proposal for public consultation – subject to change

RNAi techniques involving direct application of RNA will **not** be gene technology if they

- do not cause changes to genomic sequence
- do not allow translation of novel proteins
- do not cause formation of an infectious agent

e.g. directly applying siRNAs and dsRNA

RNAi techniques that will remain gene technology involve:

- inserting sequences into the genome and
- vector delivery.






Australian Government  
Department of Health  
Office of the Gene Technology Regulator

## What's next?

- Public consultation until February 2018 on
  - drafted amendments
  - paper outlining the directions
- Finalise amendments, taking submissions into account
  - **proposals may be modified**
- State and Territory approvals, Australian Government Regulation-making process
  - **amendments would not commence before 2019**

**Do not act on any of these proposals now.  
Always apply the current legislation!!!**







Australian Government  
Department of Health  
Office of the Gene Technology Regulator

# How can you contribute?

Technical review consultation aims to:

- fine-tune the amendment wording for best clarity and
- help us understand the impacts of these proposals.

Get involved in the Review of the National Gene Technology Scheme at

<https://consultations.health.gov.au/health-systems-policy-division/genetechreview2017/>





Australian Government  
Department of Health  
Office of the Gene Technology Regulator

# Copyright

© Commonwealth of Australia as represented by the Department of Health 2017

## Creative Commons Licence

This publication is licensed under the [Creative Commons Attribution 4.0 International Public License](http://creativecommons.org/licenses/by/4.0/legalcode) available from ([www.creativecommons.org/licenses/by/4.0/legalcode](http://www.creativecommons.org/licenses/by/4.0/legalcode)) ("Licence"). You must read and understand the Licence before using any material from this publication.

[REDACTED]

---

**From:** Institutional Biosafety Committee IBC [REDACTED]  
**Sent:** Wednesday, 20 May 2015 12:32  
**To:** MITCHELL, Heidi  
**Cc:** Iain Searle  
**Subject:** RE: Query\_Regulation of non-transgenic progeny derived from a transgenic plant [SEC=No Protective Marking]

Hi Heidi

Iain fine with you contacting him directly.

Contact details Dr Iain Searle

<http://www.adelaide.edu.au/directory/iain.searle>

<http://biological.adelaide.edu.au/research/searle/>

Regards

Virginia

---

**From:** MITCHELL, Heidi [mailto:[REDACTED]]  
**Sent:** Wednesday, 13 May 2015 5:19 PM  
**To:** Institutional Biosafety Committee IBC  
**Subject:** RE: Query\_Regulation of non-transgenic progeny derived from a transgenic plant [SEC=No Protective Marking]

Hi Virginia,

Thanks for the response. I had just found the same information from his web page. He may be looking for epigenetic effects? Are you happy if I contact him directly?

Thanks

Heidi

Dr Heidi Mitchell | Director | Plant Evaluation Section | Evaluation Branch | Office of the Gene Technology Regulator | MDP 54 | GPO Box 9848 | CANBERRA ACT 2601 | AUSTRALIA | tel. [REDACTED] fax. [REDACTED] | [REDACTED]

---

**From:** Institutional Biosafety Committee IBC [mailto:[REDACTED]]  
**Sent:** Wednesday, 13 May 2015 5:27 PM  
**To:** MITCHELL, Heidi  
**Subject:** FW: Query\_Regulation of non-transgenic progeny derived from a transgenic plant [SEC=No Protective Marking]

Hi Heidi

Thank you for the phone call re the query.

I am about to go on leave for a few days so you will get a vacation message coming up. Back at work on the 20 May.

The researcher is Dr Iain Searle

<http://www.adelaide.edu.au/directory/iain.searle>

<http://biological.adelaide.edu.au/research/searle/>

[REDACTED]

His research according to the research link is:

*We are interested in understanding the molecular mechanisms underlying reproductive development and currently focus on non-coding RNAs (miRNAs, siRNAs, long non-coding RNAs) and post-transcriptional RNA modifications.*

So you may be right in deducing that it may be genetic modifications involving RNA. But it would be nice to know why he wants to propagate the non-GM plant.

Regards  
Virginia

--  
Virginia Furness  
Research Compliance Officer (Gene Technology)  
Secretary IBC  
Office of Research Ethics, Compliance and Integrity, Research Branch  
The University of Adelaide, AUSTRALIA 5005  
[REDACTED]

Ph : [REDACTED]

Fax : [REDACTED]

e-mail: [REDACTED]

<http://www.adelaide.edu.au/ethics/genetech/>

CRICOS Provider Number 00123M

-----  
This email message is intended only for the addressee(s) and contains information which may be confidential and/or copyright. If you are not the intended recipient please do not read, save, forward, disclose, or copy the contents of this email. If this email has been sent to you in error, please notify the sender by reply email and delete this email and any copies or links to this email completely and immediately from your system. No representation is made that this email is free of viruses. Virus scanning is recommended and is the responsibility of the recipient.

*Think green: read on the screen.*

---

**From:** Institutional Biosafety Committee IBC

**Sent:** Monday, 11 May 2015 4:02 PM

**To:** 'ogtr@health.gov.au'

**Subject:** Query\_Regulation of non-transgenic progeny derived from a transgenic plant

University of Adelaide IBC is seeking advice on the following proposed research and whether it requires regulation under the GT Act.

*Are non-transgenic plant (in this case canola) progeny still required to be regulated under an IBC dealing? More information, if we have a heterozygous transgene in a canola plant, self pollinate the plant and identify progeny that do NOT contain the transgene, can we release these non-transgenic plants from PC2 containment? Ultimately I would like to release the non-transgenic plants to canola breeders.*

Regards

Virginia

--

*Virginia Furness*

Research Compliance Officer (Gene Technology)

Secretary IBC

Office of Research Ethics, Compliance and Integrity, Research Branch

The University of Adelaide, AUSTRALIA 5005

Ph : [REDACTED]

Fax : [REDACTED]

e-mail: [REDACTED]

<http://www.adelaide.edu.au/ethics/genetech/>

CRICOS Provider Number 00123M

-----  
This email message is intended only for the addressee(s) and contains information which may be confidential and/or copyright. If you are not the intended recipient please do not read, save, forward, disclose, or copy the contents of this email. If this email has been sent to you in error, please notify the sender by reply email and delete this email and any copies or links to this email completely and immediately from your system. No representation is made that this email is free of viruses. Virus scanning is recommended and is the responsibility of the recipient.

*Think green: read on the screen.*

---

"Important: This transmission is intended only for the use of the addressee and may contain confidential or legally privileged information. If you are not the intended recipient, you are notified that any use or dissemination of this communication is strictly prohibited. If you receive this transmission in error please notify the author immediately and delete all copies of this transmission."





**From:** MATTHEW, Louisa <[REDACTED]>  
**Sent:** Wednesday, 14 September 2016 11:25  
**Subject:** RE: Agenda for OGTR meeting on Monday [SEC=UNCLASSIFIED]

Hi Peter,

There's no need to go into SPT or accelerated breeding – techniques resulting in null segregants have a well-established place outside the gene technology regulatory scheme, and that's not up for review. The techniques the review will focus on are oligo-directed mutagenesis and site-directed nuclease techniques (utilising either non-homologous end-joining or homology-directed repair).

Does that sound okay to you?

Louisa

---

**From:** Peter Langridge [mailto:[REDACTED]]  
**Sent:** Wednesday, 14 September 2016 11:16 AM  
**To:** MATTHEW, Louisa  
**Subject:** RE: Agenda for OGTR meeting on Monday [SEC=UNCLASSIFIED]

Dear Louisa,

Can I just check on the technologies you would like me to cover in the presentation; was the meeting just planning to look at gene editing techniques or did you also want me to cover SPT and accelerated breeding techniques?

Cheers

Peter

---

**From:** MATTHEW, Louisa [mailto:[REDACTED]]  
**Sent:** Tuesday, 13 September 2016 3:23 PM  
**To:** [REDACTED] <[REDACTED]>; Peter Langridge <[REDACTED]>  
**Subject:** Agenda for OGTR meeting on Monday [SEC=UNCLASSIFIED]

Dear [REDACTED] and Peter,

Please find attached the agenda for the meeting at OGTR on Monday. I look forward to seeing you then,

Kind regards,  
Louisa

**Louisa Matthew**

Assistant Director, Regulatory Practice Section  
Regulatory Practice and Compliance Branch

---

Office of the Gene Technology Regulator  
Australian Government Department of Health  
T: [REDACTED] E: [REDACTED]  
Location: Pharmacy Guild House, 15 National Circuit, Barton ACT 2600

MPD 54, GPO Box 9848, Canberra ACT 2601, Australia

*The Department of Health acknowledges the traditional owners of country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to elders both past and present.*

---

"Important: This transmission is intended only for the use of the addressee and may contain confidential or legally privileged information. If you are not the intended recipient, you are notified that any use or dissemination of this communication is strictly prohibited. If you receive this transmission in error please notify the author immediately and delete all copies of this transmission."

**From:** Iain Searle <[REDACTED]>  
**Sent:** Sunday, 31 May 2015 19:45  
**To:** MITCHELL, Heidi  
**Subject:** Re: Query\_Regulation of non-transgenic progeny derived from a transgenic plant [SEC=No Protective Marking]

Dear Heidi

The parent would be transformed with a T-DNA by using *Agrobacterium tumefaciens*.

In this scenario, the T-DNA would be transformed into *Brassica rapa* and the T-DNA would contain a common plant selectable marker (BAR) and a plant promoter driving the production of dsRNA targeted to induce RNA silencing against an endogenous plant (host) gene. The trait conferred upon this transgenic parent would be the ability to produce viable hybrid seed when crossed to *Brassica oleracea*. When this seed is germinated, the hybrid plant is sterile as the two parents had different chromosome numbers unless we double the chromosomes by using a conventional chemical treatment. The segregating progeny (seeds) that contain the transgene would be discarded. Non-transgenic seed would not have the trait mentioned above. Please note these plants are actually synthetic *Brassica napus* (canola). If this is not clear I am happy to explain it further.

Best Regards,  
Iain



<http://www.genetics.org.au/2015-conference/>

Dr. Iain Searle  
Group Leader & ARC Future Fellow

\*\*\*\*\*

Dr. Iain Searle  
The University of Adelaide  
School of Biological Sciences  
School of Agriculture, Food and Wine

[REDACTED]  
Adelaide, SA 5005, Australia

E- [REDACTED]

\*\*\*\*\*

---

**From:** , Heidi <[REDACTED]>  
**Date:** Wednesday, 27 May 2015 1:20 pm  
**To:** Iain Searle <[REDACTED]>  
**Subject:** FW: Query\_Regulation of non-transgenic progeny derived from a transgenic plant [SEC=No Protective Marking]

Dear Dr Searle,  
Virginia Furness from the University of Adelaide IBC passed your query on to me about whether non-transgenic progeny are regulated as GMOs.



Please could you provide me with some more information about the process that you used to transform the plants, the introduced DNA and the trait that is present in the GM plants (and whether this is passed onto the non-transgenic progeny). This additional information will enable me to provide a response back to the IBC.

Kind regards

Heidi

Dr Heidi Mitchell | Director | Plant Evaluation Section | Evaluation Branch | Office of the Gene Technology Regulator |  
MDP 54 | GPO Box 9848 | CANBERRA ACT 2601 | AUSTRALIA | tel. [REDACTED] fax. [REDACTED]

---

**From:** Institutional Biosafety Committee IBC

**Sent:** Monday, 11 May 2015 4:02 PM

**To:** 'ogtr@health.gov.au'

**Subject:** Query\_Regulation of non-transgenic progeny derived from a transgenic plant

University of Adelaide IBC is seeking advice on the following proposed research and whether it requires regulation under the GT Act.

*Are non-transgenic plant (in this case canola) progeny still required to be regulated under an IBC dealing? More information, if we have a heterozygous transgene in a canola plant, self pollinate the plant and identify progeny that do NOT contain the transgene, can we release these non-transgenic plants from PC2 containment? Ultimately I would like to release the non-transgenic plants to canola breeders.*

Regards

Virginia

--

*Virginia Furness*

Research Compliance Officer (Gene Technology)

Secretary IBC

Office of Research Ethics, Compliance and Integrity, Research Branch

The University of Adelaide, AUSTRALIA 5005

Ph : [REDACTED]

Fax : [REDACTED]

e-mail: [REDACTED]

<http://www.adelaide.edu.au/ethics/genetech/>

CRICOS Provider Number 00123M

-----  
This email message is intended only for the addressee(s) and contains information which may be confidential and/or copyright. If you are not the intended recipient please do not read, save, forward, disclose, or copy the contents of this email. If this email has been sent to you in error, please notify the sender by reply email and delete this email and any copies or links to this email completely and immediately from your system. No representation is made that this email is free of viruses. Virus scanning is recommended and is the responsibility of the recipient.

*Think green: read on the screen.*

---

"Important: This transmission is intended only for the use of the addressee and may contain confidential or legally privileged information. If you are not the intended recipient, you are notified that any use or dissemination of this communication is strictly prohibited. If you receive this transmission in error please notify the author immediately and delete all copies of this transmission."

[REDACTED]

---

**From:** MITCHELL, Heidi  
**Sent:** Monday, 29 June 2015 13:45  
**To:** 'Iain Searle'  
**Cc:** [REDACTED]  
**Subject:** RE: Query\_Regulation of non-transgenic progeny derived from a transgenic plant [SEC=No Protective Marking]

Dear Iain,  
My apologies for the delay in responding to your query.

For the scenario that you have explained below, the segregating seeds which do not contain any transgenes would not be regarded as a GMO under the *Gene Technology Act 2000* (the Act).

The relevant legislative provision is the definition of genetically modified organism (GMO) in the Act. Section 10 of the Act defines a GMO as:

**genetically modified organism** means:

- (a) an organism that has been modified by gene technology; or
- (b) an organism that has inherited particular traits from an organism (the *initial organism*), being traits that occurred in the initial organism because of gene technology; or
- (c) anything declared by the regulations to be a genetically modified organism, or that belongs to a class of things declared by the regulations to be genetically modified organisms;

but does not include:

- (d) a human being, if the human being is covered by paragraph (a) only because the human being has undergone somatic cell gene therapy; or
- (e) an organism declared by the regulations not to be a genetically modified organisms or that belongs to a class of organisms declared by the regulations not to be genetically modified organisms.

It is my opinion that these seed which do not contain the genetic material that was introduced into the parent plant, do not fall within the definition of GMOs in section 10 of the Act. This is because these are not organisms which have themselves been modified by gene technology (paragraph (a) of the definition of a GMO) nor are they organisms that have inherited particular traits that occurred in an initial organism because of gene technology (paragraph (b) of the definition).

However the parent plant, or seed carrying any part of the genetic modification from the parent line, are GMOs and must not be imported or used in Australia without appropriate authorisation under the Act.

Please note that this response to your enquiry represents my view based on a review of the information before me at this time. It is not to be considered legal advice.

Thank you for your engagement with the regulatory system.

Kind regards

Heidi

Dr Heidi Mitchell | Director | Plant Evaluation Section | Evaluation Branch | Office of the Gene Technology Regulator | MDP 54 | GPO Box 9848 | CANBERRA ACT 2601 | AUSTRALIA | tel. [REDACTED] fax. [REDACTED]  
[REDACTED]

---

**From:** Iain Searle [mailto:[REDACTED]]  
**Sent:** Sunday, 31 May 2015 7:45 PM  
**To:** MITCHELL, Heidi  
**Subject:** Re: Query\_Regulation of non-transgenic progeny derived from a transgenic plant [SEC=No Protective Marking]

Dear Heidi

The parent would be transformed with a T-DNA by using *Agrobacterium tumefaciens*.

In this scenario, the T-DNA would be transformed into *Brassica rapa* and the T-DNA would contain a common plant selectable marker (BAR) and a plant promoter driving the production of dsRNA targeted to induce RNA silencing against an endogenous plant (host) gene. The trait conferred upon this transgenic parent would be the ability to produce viable hybrid seed when crossed to *Brassica oleracea*. When this seed is germinated, the hybrid plant is sterile as the two parents had different chromosome numbers unless we double the chromosomes by using a conventional chemical treatment. The segregating progeny (seeds) that contain the transgene would be discarded. Non-transgenic seed would not have the trait mentioned above. Please note these plants are actually synthetic *Brassica napus* (canola). If this is not clear I am happy to explain it further.

Best Regards,  
Iain



<http://www.genetics.org.au/2015-conference/>

Dr. Iain Searle  
Group Leader & ARC Future Fellow

\*\*\*\*\*

Dr. Iain Searle  
The University of Adelaide  
School of Biological Sciences  
School of Agriculture, Food and Wine

Adelaide, SA 5005, Australia

E- [REDACTED]  
\*\*\*\*\*

---

**From:** , Heidi <[REDACTED]>

**Date:** Wednesday, 27 May 2015 1:20 pm

**To:** Iain Searle <[REDACTED]>

**Subject:** FW: Query\_Regulation of non-transgenic progeny derived from a transgenic plant [SEC=No Protective Marking]

Dear Dr Searle,

Virginia Furness from the University of Adelaide IBC passed your query on to me about whether non-transgenic progeny are regulated as GMOs.

Please could you provide me with some more information about the process that you used to transform the plants, the introduced DNA and the trait that is present in the GM plants (and whether this is passed onto the non-transgenic progeny). This additional information will enable me to provide a response back to the IBC.

Kind regards

Heidi



---

**From:** Institutional Biosafety Committee IBC

**Sent:** Monday, 11 May 2015 4:02 PM

**To:** 'ogtr@health.gov.au'

**Subject:** Query\_Regulation of non-transgenic progeny derived from a transgenic plant

University of Adelaide IBC is seeking advice on the following proposed research and whether it requires regulation under the GT Act.

*Are non-transgenic plant (in this case canola) progeny still required to be regulated under an IBC dealing? More information, if we have a heterozygous transgene in a canola plant, self pollinate the plant and identify progeny that do NOT contain the transgene, can we release these non-transgenic plants from PC2 containment? Ultimately I would like to release the non-transgenic plants to canola breeders.*

Regards

Virginia

--

*Virginia Furness*

Research Compliance Officer (Gene Technology)

Secretary IBC

Office of Research Ethics, Compliance and Integrity, Research Branch

The University of Adelaide, AUSTRALIA 5005

[REDACTED]  
Ph : [REDACTED]

Fax : [REDACTED]

e-mail: [REDACTED]

<http://www.adelaide.edu.au/ethics/genetech/>

CRICOS Provider Number 00123M

-----  
This email message is intended only for the addressee(s) and contains information which may be confidential and/or copyright. If you are not the intended recipient please do not read, save, forward, disclose, or copy the contents of this email. If this email has been sent to you in error, please notify the sender by reply email and delete this email and any copies or links to this email completely and immediately from your system. No representation is made that this email is free of viruses. Virus scanning is recommended and is the responsibility of the recipient.

*Think green: read on the screen.*

---

"Important: This transmission is intended only for the use of the addressee and may contain confidential or legally privileged information. If you are not the intended recipient, you are notified that any use or dissemination of this

communication is strictly prohibited. If you receive this transmission in error please notify the author immediately and delete all copies of this transmission."

[REDACTED]

---

**From:** ROBOLD, Andrea [REDACTED] >  
**Sent:** Tuesday, 5 December 2017 8:52  
**Subject:** RE: CSIRO Gene editing of crops Kiama workshop - feedback requested and pdfs available on website [SEC=UNCLASSIFIED]  
**Attachments:** Kiama 2017 OGTR.pptx  
**Follow Up Flag:** Follow up  
**Flag Status:** Flagged

Dear Steve

Thank you again for putting together this workshop – it was very interesting from a research point, but also felt that it was well rounded because you included people from regulatory agencies and social scientists.

I apologise for the delay in giving permission to upload my presentation.

I have made a change to slide no 13 which explains the directions we had at the time on how SDN technologies are proposed to be regulated. I did so, because I was unsure if people understood me correctly and it is important that regulatory requirements are clear to everyone. Could you please make the attached presentation available to the attendees of the workshop?

Regards  
Andrea

---

**From:** Steve.Jobling [REDACTED] [mailto:[REDACTED]]  
**Sent:** Monday, 4 December 2017 4:48 PM  
**To:** [REDACTED]

[REDACTED]

**Subject:** CSIRO Gene editing of crops Kiama workshop - feedback requested and pdfs available on website [SEC=No Protective Marking]

Dear participants, I hope you all enjoyed the workshop as much as we did and you all got home safely, especially the overseas visitors.

As was said at the end of the meeting, we would be grateful for feedback on the event especially on topics such as:

- Quality of speakers
- How well the meeting performed as a forum for making new contacts and potential collaborations
- How the Q&A sessions were received both from a regulatory/ethics and science/technical perspective
- Feedback from the regulators and departmental officials would be especially welcomed as a key reason behind the workshop was to discuss issues and inform them of developments in the gene editing field.
- Should we hold the event again perhaps in 2-3 years?

PDFs of the presentations are now uploaded to the website <https://research.csiro.au/gene-editing-workshop/> along with a couple of photos from the workshop. If anyone has other photos they think would add to the appearance of the website please forward them and we may add them – perhaps in a separate page?

Please remember that the website has a list of contact details so we can help build a gene editing community in Australia and New Zealand.

On that note, if participants are willing to share the vectors and experience they have in gene editing, then please send us the details and we will upload to the website. Please include ;

- Vector name (Agro/biolistic)
- Species transformed and approx. efficiency of editing
- sgRNA system (source of U3/U6 promoters, single multiple cassettes etc
- conditions of use (MTA etc).

Please note that CSIRO requires a signed MTA before any material is exchanged with a CSIRO party.

Regards

Steve Jobling  
Filomena Pettolino  
Ming Luo

The organising committee

**PLEASE NOTE**

The information contained in this email may be confidential or privileged. Any unauthorised use or disclosure is prohibited. If you have received this email in error, please delete it immediately and notify the sender by return email. Thank you. To the extent permitted by law, CSIRO does not represent, warrant and/or guarantee that the integrity of this communication has been maintained or that the communication is free of errors, virus, interception or interference.

*Please consider the environment before printing this email.*